Paromomycin for cryptosporidiosis in aids: A prospective, double-blind trial

A. Clinton White, Cynthia L. Chappell, C. Sikander Hayat, Kay T. Kimball, Timothy P. Flanigan, Richard W. Goodgame

Research output: Contribution to journalArticlepeer-review

182 Scopus citations


To test the effects of paromomycin, 10 patients with AIDS and cryptosporidiosis were randomized to paromomycin or placebo in a double-blind trial. After 14 days, patients were switched to the other treatment for 14 additional days. Measures included the number and character of each stool and weekly 24-h stool specimens for weight and oocyst excretion. During the paromomycin treatment phase, oocyst excretion decreased from 314 X 106 to 109 X 106 /24 h (P<.02). Oocyst excretion increased for the 4 patients initially on placebo compared to a median decrease of 128 X 106 /24 h for the 6 initially treated with drug (P<.02). Stool frequency also decreased more in those treated with drug (3.6 fewer vs. 1.25 fewer/24 h, P<.05). Trends favored drug over placebo for stool weight, stool character, and Karnofsky score. Paromomycin treatment resulted in improvement in both clinical and parasitologic parameters in cryptosporidiosis in AIDS.

Original languageEnglish (US)
Pages (from-to)419-424
Number of pages6
JournalJournal of Infectious Diseases
Issue number2
StatePublished - Aug 1994
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Paromomycin for cryptosporidiosis in aids: A prospective, double-blind trial'. Together they form a unique fingerprint.

Cite this